Published in J Neurosci Res on March 15, 1999
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Methamphetamine toxicity and messengers of death. Brain Res Rev (2009) 2.69
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev (2014) 1.96
Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci U S A (2006) 1.88
Decreased catecholamine degradation associates with shock and kidney injury after cardiac surgery. J Am Soc Nephrol (2009) 1.60
Chemistry of periodate-mediated cross-linking of 3,4-dihydroxylphenylalanine-containing molecules to proteins. J Am Chem Soc (2006) 1.60
Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol (2007) 1.59
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One (2008) 1.32
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation (2006) 1.32
The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons. Neurobiol Dis (2010) 1.31
Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med (2008) 1.25
Glutathione metabolism and Parkinson's disease. Free Radic Biol Med (2013) 1.20
S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci U S A (2009) 1.20
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J Biol Chem (2011) 1.19
The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol (2008) 1.11
Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis (2009) 1.11
Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma (2011) 1.08
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav (2007) 1.07
Evidence for oxidative stress in tissues derived from succinate semialdehyde dehydrogenase-deficient mice. J Inherit Metab Dis (2007) 1.06
Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J Neuroinflammation (2009) 1.05
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J Bioenerg Biomembr (2009) 1.05
Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry (2011) 1.03
Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry (2011) 1.02
3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci (2009) 0.97
Computational systems analysis of dopamine metabolism. PLoS One (2008) 0.96
Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett (2009) 0.96
Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis (2007) 0.95
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther (2014) 0.94
skn-1-Dependent and -independent regulation of aip-1 expression following metabolic stress in Caenorhabditis elegans. Mol Cell Biol (2010) 0.93
Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care (2004) 0.91
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol Dis (2014) 0.90
A neuroinductive biomaterial based on dopamine. Proc Natl Acad Sci U S A (2006) 0.90
Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease. Int J Mol Sci (2010) 0.89
Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies. Parkinsons Dis (2011) 0.89
Oxidative stress biomarkers in some rat brain structures and peripheral organs underwent cocaine. Neurotox Res (2012) 0.88
Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology (2011) 0.87
Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem Res (2008) 0.87
Mechanisms of neuronal death in synucleinopathy. J Biomed Biotechnol (2006) 0.87
Genetically engineered mouse models of Parkinson's disease. Brain Res Bull (2011) 0.86
Structure Effect on Antioxidant Activity of Catecholamines toward Singlet Oxygen and Other Reactive Oxygen Species in vitro. J Clin Biochem Nutr (2010) 0.85
Complex molecular regulation of tyrosine hydroxylase. J Neural Transm (Vienna) (2014) 0.85
MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression. Free Radic Biol Med (2015) 0.84
Selenoproteins in nervous system development and function. Biol Trace Elem Res (2014) 0.84
Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. J Neurochem (2010) 0.84
L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology (2012) 0.84
Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals. Synapse (2009) 0.83
Environmental and behavioral modulation of the number of substantia nigra dopamine neurons in adult mice. Brain Behav (2013) 0.83
The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior. Eur J Neurosci (2008) 0.80
ROS initiated oxidation of dopamine under oxidative stress conditions in aqueous and lipidic environments. J Phys Chem B (2011) 0.79
A dopamine receptor contributes to paraquat-induced neurotoxicity in Drosophila. Hum Mol Genet (2014) 0.79
The effects of locus coeruleus and norepinephrine in methamphetamine toxicity. Curr Neuropharmacol (2013) 0.79
Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities. Biochim Biophys Acta (2011) 0.78
Expression and functional activities of selected sulfotransferase isoforms in BeWo cells and primary cytotrophoblast cells. Biochem Pharmacol (2009) 0.78
Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase. Toxicol Sci (2015) 0.78
Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. Neurotox Res (2009) 0.76
SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies. Neurosci Lett (2013) 0.76
MicroRNAs in Parkinson's disease. Exp Brain Res (2017) 0.76
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol Commun (2017) 0.75
Ozone inhalation modifies the rat liver proteome. Redox Biol (2013) 0.75
The AS/AGU rat: a spontaneous model of disruption and degeneration in the nigrostriatal dopaminergic system. J Anat (2000) 0.75
Cell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animals. PLoS One (2014) 0.75
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochem Res (2016) 0.75
Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease? Curr Genomics (2009) 0.75
Manganese inhalation as a Parkinson disease model. Parkinsons Dis (2010) 0.75
Parkinson's disease: genetics and beyond. Curr Neuropharmacol (2007) 0.75
N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochem Res (2017) 0.75
E3 Ubiquitin Ligases Neurobiological Mechanisms: Development to Degeneration. Front Mol Neurosci (2017) 0.75
Quantitative RT-PCR: pitfalls and potential. Biotechniques (1999) 11.98
Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry (1982) 2.37
Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci (1995) 2.31
Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem (1996) 2.11
Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci (1999) 1.76
Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem (1999) 1.74
Manganese uptake and distribution in the central nervous system (CNS). Neurotoxicology (1999) 1.58
Chronic cocaine-mediated changes in non-human primate nucleus accumbens gene expression. J Neurochem (2001) 1.24
Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res (1998) 1.14
Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem (1995) 1.09
Quantitative biochemical and ultrastructural comparison of mitochondrial permeability transition in isolated brain and liver mitochondria: evidence for reduced sensitivity of brain mitochondria. Exp Neurol (2000) 1.05
Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem (1996) 1.04
Fundamentals of DNA hybridization arrays for gene expression analysis. Biotechniques (2000) 1.03
Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J Neurochem (1993) 1.03
Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. Neurochem Res (1997) 1.02
Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp Neurol (1998) 1.01
Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience (2000) 0.99
Cocaine-responsive gene expression changes in rat hippocampus. Neuroscience (2001) 0.98
Tyrosinase mRNA is expressed in human substantia nigra. Brain Res Mol Brain Res (1997) 0.93
Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J Neurochem (1999) 0.92
Advances in the molecular characterization of tryptophan hydroxylase. J Mol Neurosci (1998) 0.92
Role of endogenous glutathione in the oxidation of dopamine. J Neurochem (1998) 0.91
A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes. Neuroscience (2006) 0.91
Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis. Brain Res (2000) 0.89
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Ann N Y Acad Sci (1992) 0.89
Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration. J Neurochem (1999) 0.87
Catalytic core of rat tyrosine hydroxylase: terminal deletion analysis of bacterially expressed enzyme. Biochim Biophys Acta (1994) 0.86
Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol (1997) 0.85
p-ethynylphenylalanine: a potent inhibitor of tryptophan hydroxylase. J Neurochem (2000) 0.85
PCR-based apolipoprotein E genotype analysis from archival fixed brain. J Neurosci Methods (1998) 0.84
Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J Neurochem (1997) 0.84
Effects of vasopressin and elimination of corticotropin-releasing hormone-target cells on pro-opiomelanocortin mRNA levels and adrenocorticotropin secretion in ovine anterior pituitary cells. J Endocrinol (1997) 0.83
Identification of substrate orienting and phosphorylation sites within tryptophan hydroxylase using homology-based molecular modeling. J Mol Biol (2000) 0.83
Radioenzymatic assay for tryptophan hydroxylase: [3H]H2O release assessed by charcoal adsorption. J Neurosci Methods (1993) 0.82
Amino-terminal analysis of tryptophan hydroxylase: protein kinase phosphorylation occurs at serine-58. J Neurochem (1997) 0.82
Neurochemical responses to lesions of dopaminergic neurons: implications for compensation and neuropathology. Adv Pharmacol (1998) 0.82
Involvement of ecto-phosphoryl transfer in contractions of the smooth muscle of the guinea pig vas deferens to adenosine 5'-triphosphate. J Pharmacol Exp Ther (1991) 0.82
A chimeric tyrosine/tryptophan hydroxylase. The tyrosine hydroxylase regulatory domain serves to stabilize enzyme activity. J Mol Neurosci (1997) 0.82
Pituitary corticotroph function during the stress hyporesponsive period in neonatal rats. Neuroendocrinology (1993) 0.81
Tyrosine hydroxylase inactivation following cAMP-dependent phosphorylation activation. J Neurochem (1983) 0.81
Tyrosine hydroxylase activation and inactivation by protein phosphorylation conditions. J Neurochem (1981) 0.81
Leucine zippers and coiled-coils in the aromatic amino acid hydroxylases. Neurochem Int (1991) 0.80
Application of quantitative RT-PCR to the analysis of dopamine receptor mRNA levels in rat striatum. Brain Res Mol Brain Res (1995) 0.79
Carboxyl terminal deletion analysis of tryptophan hydroxylase. Biochim Biophys Acta (1997) 0.79
Identification of the phosphoserine residue in histone H1 phosphorylated by protein kinase C. FEBS Lett (1988) 0.78
Use of elevated reverse transcription reaction temperatures in RT-PCR. Biotechniques (1996) 0.78
Identification of a ternary complex between cAMP and a trimeric form of cAMP-dependent protein kinase. J Biol Chem (1986) 0.77
Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Mol Pharmacol (1992) 0.77
Examination of a CYP2E1 repeat polymorphism in a monkey model of alcohol abuse. Alcohol Clin Exp Res (2001) 0.77
How the regulatory and catalytic domains get together. Nat Struct Biol (1999) 0.77
Identification of amino-terminal sequences contributing to tryptophan hydroxylase tetramer formation. J Mol Neurosci (1999) 0.76
Tyrosinase enhances the covalent modification of DNA by dopamine. Brain Res Mol Brain Res (1996) 0.76
Adrenocorticotropin and corticosterone levels in pre-weanling spontaneously hypertensive rats. Life Sci (1989) 0.76
Gender-specific regulation of tyrosine hydroxylase in thymocyte differentiation antigen-1 knockout mice. J Neurosci Res (2012) 0.75
A cocaine analog, 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT), reduces tyrosine hydroxylase in the mesolimbic dopamine pathway. Drug Alcohol Depend (2000) 0.75
Paraoxon-induced decrease in the muscarinic acetylcholine receptor content in rat heart. Eur J Pharmacol (1987) 0.75
High efficiency transient expression of eukaryotic genes: use of an HSV-1 immediate early promoter (ICP4). Biotechniques (1990) 0.75
Effects of morphine on forskolin-stimulated pro-enkephalin mRNA levels in rat striatum: a model for acute and chronic opioid actions in brain. Brain Res Mol Brain Res (1995) 0.75
Inactivation of tyrosine hydroxylase by pterin substrates following phosphorylation by cyclic AMP-dependent protein kinase. Mol Pharmacol (1990) 0.75
Expression of preproNPY and precursor VIP mRNAs in rats under hypo- or hyperthyroid conditions. Mol Cell Neurosci (1992) 0.75
AF-DX 384 binding in rabbit cingulate cortex: two site kinetics and section autoradiography. J Pharmacol Exp Ther (1995) 0.75
Acidosis-induced metallothionein (MT) mRNA expression in neonatal rat primary astrocyte cultures. Neurotoxicology (1998) 0.75
Intersubunit binding domains within tyrosine hydroxylase and tryptophan hydroxylase. J Neurosci Res (2000) 0.75
Tyrosine hydroxylase and tryptophan hydroxylase do not form heterotetramers. J Mol Neurosci (1998) 0.75